Biocon says may have to delay biologics biz IPO

Biocon says may have to delay biologics biz IPO Biocon’s biologics business has been hit unexpectedly hard due to the pandemic and if the business does not meet our desired growth trajectory, we may defer its IPO (initial public offering) by a few quarters, the company’s executive chairperson Kiran Mazumdar-Shaw said. https://ift.tt/eA8V8J